Urgent

Pulmonary tuberculosis (active, drug-susceptible) — treatment & workup

pulmonary-tb-active · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Active pulmonary TB caused by Mycobacterium tuberculosis — distinct from the existing miliary/disseminated and TB-meningitis entries. Standard drug-susceptible treatment is a 2-month intensive phase (HRZE) then 4-month continuation (HR), with modern rapid molecular diagnostics, DOT/adherence support, and public-health notification. A WHO 4-month rifapentine-moxifloxacin regimen is an alternative in eligible patients.

Red flags

  • Rifampicin or multi-drug resistance on molecular testing
  • Massive haemoptysis
  • Respiratory failure / extensive disease / impending airway compromise
  • Drug-induced hepatitis (nausea, jaundice, rising transaminases)
  • HIV co-infection / immunosuppression
  • Treatment non-response or relapse (suspect resistance or non-adherence)

Assessment

Differential diagnosis

  • Community-acquired / aspiration pneumonia
  • Lung cancer
  • Non-tuberculous mycobacterial disease
  • Lung abscess
  • Fungal infection (histoplasmosis, aspergilloma)
  • Sarcoidosis
  • Bronchiectasis
  • Pulmonary vasculitis

Investigations

  • Rapid molecular test on sputum (Xpert MTB/RIF Ultra or similar) — detects M. tuberculosis AND rifampicin resistance; first-line diagnostic
  • Sputum smear microscopy (AFB) x2 and mycobacterial culture + phenotypic/molecular drug-susceptibility testing
  • CXR (upper-lobe infiltrates/cavitation; any pattern possible); consider CT if doubt
  • HIV test in ALL TB patients; screen diabetes (esp. India), hepatitis B/C
  • Baseline LFTs, U&E, FBC, visual acuity + colour vision (ethambutol); weight (for weight-banded dosing)
  • Contact tracing and public-health notification
  • Sputum conversion monitoring (smear/culture) at end of intensive phase

Management

  • Isolate respiratory (airborne precautions, negative-pressure if available) while infectious
  • Confirm with rapid molecular test; start treatment promptly in strongly suspicious/confirmed cases without waiting for culture
  • Standard regimen: 2 months isoniazid + rifampicin + pyrazinamide + ethambutol (HRZE), then 4 months isoniazid + rifampicin (HR); use weight-banded fixed-dose combinations (NTEP/India, WHO)
  • Add pyridoxine to prevent isoniazid neuropathy
  • Arrange directly observed / supported treatment and adherence support; counsel on duration and side-effects
  • Monitor: symptoms, weight, adherence, LFTs if symptomatic/at risk, visual function on ethambutol; repeat sputum to confirm conversion
  • If rifampicin resistance detected -> drug-resistant TB pathway (BPaLM/BPaL-based regimens)
  • Notify public health; screen and manage contacts; treat latent TB in appropriate contacts
  • Manage HIV co-infection with ART (watch rifampicin drug interactions) and co-trimoxazole prophylaxis as indicated

Drugs & doses

Isoniazid 5 mg/kg PO once daily (max 300 mg) — intensive + continuation phase
Rifampicin 10 mg/kg PO once daily (max 600 mg)
Pyrazinamide 25 mg/kg PO once daily (intensive phase only)
Ethambutol 15 mg/kg PO once daily (intensive phase; counsel re visual symptoms)
Weight-banded 4-drug fixed-dose combination (HRZE) in intensive phase, HR FDC in continuation — per NTEP/WHO bands [verify local weight band]
Pyridoxine 10-25 mg PO once daily throughout (prevents INH neuropathy)
Alternative WHO 4-month regimen: isoniazid + rifapentine + moxifloxacin + pyrazinamide (2HPMZ/2HPM) in eligible patients >=12 yr [verify current WHO/local eligibility]

Disposition

Notify and manage via TB service / DOTS programme; most treated as outpatients with adherence support. Admit for haemoptysis, respiratory failure, drug toxicity, severe comorbidity, or infection-control needs. Isolate while infectious.

Complications & pitfalls

  • Drug-induced hepatotoxicity (stop hepatotoxic drugs if ALT >5x ULN, or >3x with symptoms)
  • Ethambutol optic neuropathy; isoniazid peripheral neuropathy
  • Haemoptysis, bronchiectasis, aspergilloma, fibrosis/destroyed lung
  • Drug resistance from inadequate treatment
  • Immune reconstitution inflammatory syndrome (HIV co-infection on ART)
  • Transmission to contacts

Exam pearls

  • Standard drug-susceptible pulmonary TB = 2HRZE/4HR (6 months total) with DOT/adherence support (WHO Consolidated TB guidelines; India NTEP).
  • Use a rapid molecular test (Xpert MTB/RIF Ultra) up front — it diagnoses TB and detects rifampicin resistance within hours.
  • Test EVERY TB patient for HIV and screen for diabetes (strong driver of TB in India).
  • If rifampicin resistance is found, switch to the shorter all-oral regimens (WHO 2024: 6-month BPaLM, with moxifloxacin dropped if fluoroquinolone resistance) — verify current WHO/local guidance.
  • A WHO 4-month rifapentine-moxifloxacin-containing regimen is an option for eligible drug-susceptible patients >=12 years — confirm against the current guideline before use.
  • Rifampicin is a potent enzyme inducer — review interactions (ART, warfarin, oral contraceptives, many others).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.